Immunotherapy for Prostate Cancer — Why It Rarely Works

For most men with prostate cancer, no. Immunotherapy is not part of standard treatment for prostate cancer at any stage. Prostate cancer is one of the least responsive solid tumours to checkpoint inhibitor drugs. One narrow exception exists, and it is found by a laboratory test on tumour tissue rather than by asking for the treatment.

This page leads with the disappointing answer deliberately. Immunotherapy has changed first-line care in several cancers, and that news travels. Families assume it applies everywhere and arrive asking for a treatment their relative cannot benefit from. Here the honest answer is the useful one, and it saves money and time a man with advanced disease cannot spare.

Large randomised studies of checkpoint inhibitors in unselected advanced prostate cancer have not reproduced the effect seen in cancers such as lung, kidney and melanoma. That is why guideline bodies including NCCN, ASCO and ESMO do not place immunotherapy in the routine treatment pathway for prostate cancer.

What is standard instead depends on stage: active surveillance, surgery or radiotherapy for disease confined to the prostate; hormonal treatment, chemotherapy, radiotherapy to symptomatic sites and bone-protective treatment for advanced disease; and, in selected cases, targeted or radioligand approaches. None of those are immunotherapy, and none of them become immunotherapy because a brochure calls them advanced.

Nothing on this page decides eligibility. That rests on the pathology report, the stage, previous treatment and overall fitness, read together by a medical oncologist.

Because there is very little for the immune system to recognise. Checkpoint inhibitors do not attack cancer directly. They release brakes on immune cells that are already trying to act. That only helps when immune cells can identify the tumour in the first place. Prostate cancer gives them almost nothing to work with.

Oncologists call this a cold tumour. It is not one flaw but four, and they compound each other.

A fifth factor is harder to tabulate. Bone-only disease is difficult to measure on scans, so even where something is happening it is hard to demonstrate. That has slowed research here as well as treatment.

This is biology, not pessimism — and it is why a biomarker result can overturn the answer for one man when a general argument never could.

Yes, and they are narrow. The established exception is advanced prostate cancer that is mismatch repair-deficient or MSI-high. NCCN recognises a tissue-agnostic role for immunotherapy in those tumours, meaning the biomarker matters more than the organ the cancer started in. Everything else on this list is rarer, or still investigational.

• Mismatch repair-deficient or MSI-high disease — the one exception with settled guideline standing. Covered in full in the next section, because it is also the one worth actively testing for.
• High tumour mutational burden — a rarer group, sometimes overlapping with the first. Where a sequencing panel reports a high mutational burden, immunotherapy may be raised as a tissue-agnostic option, and the same regulatory caveat applies.
• Tumours carrying CDK12 alterations — an area of active research rather than standard care. The evidence is immature and inconsistent. It should be discussed as investigational, never presented as an established option.
• Clinical trials — most current work pairs immunotherapy with another treatment to try to warm a cold tumour. Your oncologist or the trial registry can tell you what is open. This page is informational: it does not recruit, and no investigational combination should be described to you as proven.

Where a case does fall into the exception group, delivery is unremarkable and deliberately routine. Immunotherapy is given as day care at CION centres. Bloods are checked to protocol at baseline and again before every cycle — thyroid, liver, blood counts and kidney function including creatinine and eGFR — and response is assessed on imaging coordinated at partner imaging centres, at set points rather than on request.

The mirror image of this page exists in colorectal cancer, where the same biomarker decides the answer in the opposite direction for the majority. MSS Colorectal Cancer: Why Immunotherapy Does Not Work explains how one test result rules most patients out there too.

This is the group where immunotherapy is genuinely considered. Published series put mismatch repair-deficient or MSI-high disease at under 5 in 100 advanced prostate cancers. Uncommon, but not negligible. It is identified on tumour tissue. It cannot be read off a PSA value and it does not show on a scan.

Mismatch repair is the cell's spell-checker. When it stops working, errors accumulate every time the cell divides, and the tumour ends up carrying far more mutations than a typical prostate cancer. That is exactly the deficiency described in the table above, reversed. A tumour with a heavy mutation load looks abnormal to immune cells, so releasing the brake can achieve something.

Two labels describe the same problem from different directions. dMMR means the repair proteins are missing when the pathologist stains for them. MSI-high means the genetic consequence of that loss is measurable in DNA. Either result puts a case in the exception group.

Where the result is positive, immunotherapy moves from irrelevant to a real option. It is usually discussed after standard hormonal and chemotherapy approaches rather than in place of them, and it is a tumour-board decision at CION rather than one doctor's call. Benefit is still described, not promised: some men in this group respond well and durably, others do not, and no page can tell you in advance which applies to you.

There is a second reason the test matters. A dMMR result can point to Lynch syndrome, an inherited condition that raises cancer risk in blood relatives. Genetic counselling is normally offered alongside the result, and it is worth accepting even when the immunotherapy question turns out negative — the information belongs to your family as much as to you.

Several, and the confusion is understandable. Newer prostate cancer treatments are often described as advanced, precision or targeted, and patients reasonably hear immunotherapy in that. None of the four below work through the immune system, and knowing which is which changes the questions you ask.

• Hormonal therapy is not immunotherapy — it lowers or blocks the testosterone that prostate cancer feeds on. It is the backbone of advanced prostate cancer treatment and among the most effective things available, but it acts on hormones, not on immune cells.
• The PARP inhibitor class is targeted therapy — these tablets exploit a fault in the tumour's own DNA-repair machinery, in men whose cancer carries specific DNA-repair gene alterations. Also biomarker-selected, also found by testing, but a different mechanism entirely.
• PSMA-targeted radioligand therapy is radiation, delivered intravenously — a molecule that seeks out prostate cancer cells carries a radioactive payload to them. It sounds like a smart missile, which is close to true, but nothing about it involves the immune system.
• Bone-strengthening injections protect the skeleton — they reduce fractures and bone events in advanced prostate cancer. They are supportive treatment, not anti-cancer immune treatment.

One more distinction is worth making because it comes up in this same specialty. Bladder cancer has used an immune-based treatment instilled directly into the bladder for decades, and it works. Prostate and bladder sit inches apart anatomically and could not be further apart on this question.

Cost only becomes a real question once the exception applies. For the urological cancers where immunotherapy does have a defined role, indicative figures — indicative only, as of August 2026 — are set out in Cost of Immunotherapy for Kidney and Bladder Cancer.

• Colorectal cancer runs on the same biomarker as the prostate exception, and rules most patients out on it — MSS Colorectal Cancer: Why Immunotherapy Does Not Work is the closest parallel to this page.
• Liver cancer sits at the opposite end, where immunotherapy-based treatment has moved into the first line — Immunotherapy for Liver Cancer (Hepatocellular Carcinoma) shows what a responsive cancer looks like.
• If the question behind your question is money, the urological cost page carries indicative figures and scheme cover — Cost of Immunotherapy for Kidney and Bladder Cancer.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to a specific prostate cancer diagnosis? Book a free consultation and a medical oncologist will go through the reports with you.